Pancreatic ductal adenocarcinoma (PDAC) cell lines, MIA PaCa-2, and UK Pan-1, were used to investigate the role of ErbB2 in PDAC oncogenesis. Both these cell lines exhibit exogenous growth factor-independent proliferation that was attributed to the production of autocrine growth factors and/or overexpression of growth factor receptors. The exogenous growth factor-independent phenotype displayed by these PDAC cell lines was dependent on ErbB2 kinase activity since treatment of cells with tyrphostin AG879 prevented serum-free media (SFM) induction of cell proliferation. We determined that ErbB2 kinase contributed to aberrant cell cycle regulation in PDAC through the induction of cyclin D1 levels and the suppression of p21 Cip1 and p27 Kip1 . Inhibition of ErbB2 kinase led to cell cycle arrest marked by an increased association of p27
Introduction
The ErbB family of Type 1 receptor tyrosine kinases (RTKs) includes four members, EGFR (ErbB1), ErbB2 (HER2/neu), ErbB3, and ErbB4, which share a similar primary structure and are widely expressed in human tissues. A number of ErbB ligands have also been identified that bear homology to EGF, but differ in their affinity for ErbB family members. The precise nature of ErbB ligand/receptor interactions is a subject of ongoing investigation but, in general, ErbB ligand binding is thought to induce the dimerization or oligomerization of ErbB receptors, both in hetero-oligomers or homooligomers of varying ErbB receptor combinations. The receptors then undergo phosphorylation on tyrosine residues due to their intrinsic tyrosine kinase activity. The phosphorylation of specific tyrosine residues on ErbB receptors establishes docking sites for the activation of intracellular signaling pathways that regulate a host of cellular functions. ErbB2 differs from the other ErbB receptors in that to date it is without an identified, soluble ligand, yet appears to be the preferred dimerization partner for the other ErbB receptors in their ligandbound state and acts generally to potentiate and prolong ErbB signaling (Brennan et al., 2000; Klapper et al., 2000) .
ErbB2 overexpression has been observed in numerous human cancers where it is associated with multiple drug resistance, higher metastatic potential, and decreased patient survival times (Hynes and Stern, 1994; Klapper et al., 2000) . The cellular mechanisms of ErbB2-associated tumorigenicity remain to be elucidated in their full scope but seem to involve at least in part the maintenance of aberrantly activated intracellular mitogenic signaling pathways. The overexpression of ErbB2 alongside the overexpression of other ErbB family members, particularly epithelial growth factor receptor (EGFR), leads to greatly augmented proliferative and cell-survival signaling and synergistic transforming effects (Hung et al., 1989; Kokai et al., 1989) . ErbB2 overexpression alone, upon reaching a certain threshold (>10 6 receptors/cell), may also independently lead to cellular transformation by allowing for the spontaneous formation of receptor dimers/oligomers (Di Fiore et al., 1987; Di Marco et al., 1990) .
Aberrant ErbB2 expression in pancreatic ductal adenocarcinoma (PDAC) has been reported in a number of studies, with a prevalence ranging from 7 to 58% (Hall et al., 1990; Satoh et al., 1993; Yamanaka et al., 1993; Jaskiewicz et al., 1994; Dugan et al., 1997) . The ErbB2 overexpression observed in PDAC, although associated with higher ErbB2 mRNA levels, is rarely linked to ErbB2 gene amplification unlike breast, colon, and ovarian cancers (Hall et al., 1990; Yamanaka et al., 1993) . ErbB2 overexpression in PDAC, similar to breast and gastric cancer, has been correlated with more glandular, well-differentiated tumor histology (Dugan et al., 1997) . A high percentage of intraductal pancreatic lesions demonstrate ErbB2 expression, particularly intraductal mucin-hypersecreting neoplasms, which, like comedo-type ductal carcinoma in situ (DCIS) in the breast, may represent an early-stage or precursor lesion to invasive cancers (Somerville et al., 1992; Satoh et al., 1993) . However, ErbB2 expression does not correlate with a statistically significant decrease in survival time in PDAC unlike breast cancer, although it has been suggested that this is due to the universally poor prognosis for PDAC regardless of tumor stage or grade (Kloppel et al., 1985; Dugan et al., 1997) . The survival differences between well and poorly differentiated tumors in PDAC are slight at 1-year and absent at 5-year intervals (Kloppel et al., 1985) . However, significant survival differences have been noted between PDAC and closely related tumors of the papilla of Vater, which do not show overexpression of ErbB2 or EGFR (Friess et al., 1999) . Overexpression of EGFR, EGF, and TGFa has also been reported in PDAC (Korc et al., 1992) . Importantly, no studies to date have examined the role that ErbB2 plays in PDAC in promoting tumorigenesis at the cellular level.
ErbB2-associated proliferative signaling contributes to cellular transformation in human cancers through the aberrant regulation of cell cycling (reviewed in (Busse et al., 2000; Harari and Yarden, 2000) . D-type cyclins, which serve the dual functions of pRb phosphorylation in early G1 and facilitation of cyclin E kinase activity through the sequestering of cyclin-dependent kinase inhibitors (ckis), are induced by a number of mitogenic stimuli including those associated with ErbB2 (reviewed in Sherr and Roberts, 1999) . DCIS breast lesions, which exhibit a high frequency of ErbB2 overexpression (Allred et al., 1992; Mack et al., 1997) , display concomitant cyclin D1 overexpression in the vast majority of cases (Weinstat-Saslow et al., 1995; Worsley et al., 1997) . Additionally, breast cell lines transfected with oncogenic ErbB2 showed a marked increase in the level of cyclin D1 protein (Lee et al., 2000) . ErbB2 signaling targets have been shown to upregulate the expression of D-type cyclins at the transcriptional level and by post-translational stabilization (Albanese et al., 1995; Cheng et al., 1998; Diehl et al., 1998; Gjoerup et al., 1998; Aziz et al., 1999; Gartel et al., 2000; Lee et al., 2000) . The end result of D-type cyclin overexpression is to lessen tumor cell dependency on mitogenic stimuli for cell-cycle entrance and thereby to enhance cellular proliferation (Bartkova et al., 1997; Sherr and Roberts, 1999) . Aberrant expression of the cdk inhibitors p21
Cip1 and p27
Kip1
, induced by ErbB2 signaling, has also been reported (Harari and Yarden, 2000) . In the case of the ckis, both induction and repression may result in conjunction with ErbB2 signaling, most likely owing to the observed stoichiometric effects of these proteins on cyclin-dependent kinase (cdk) activity. Low levels of ckis have been shown to activate cyclin D/cdk4 complexes (Zhang et al., 1994) , and the association of cyclin D1 with cdk4 is inhibited in the absence of ckis (LaBaer et al., 1997; Cheng et al., 1999) . However, high levels of ckis may overwhelm the sequestering capacity of D-type cyclins allowing ckis to bind to cyclin E-cdk2 complexes and resulting in G1 arrest (Xiong et al., 1993) . Thus, the modulation of cki levels by ErbB2 involves a balancing act that leads ultimately to optimization of cell proliferation and cell survival.
ErbB-associated proliferative signaling is classically linked to the Ras/MAPK and AKT pathways, both of which have been shown to promote increased cyclin D1 levels and cell-cycle progression (Harari and Yarden, 2000) . More recently, however, the role of STATs in ErbB mitogenic signaling has been explored in greater depth.
STATs are a family of transcription factors that were initially investigated in the setting of cytokine signaling, where the mechanism of their activation has been well characterized (Darnell Jr, et al., 1994; Darnell Jr, 1997) . Cytokine receptors undergo dimerization/oligomerization in response to ligand binding and recruit the binding of Janus activated kinases (JAKs) to their intracellular domains. As cytokine receptors lack intrinsic tyrosine kinase activity, their tyrosine phosphorylation is dependent on JAKs (Ihle et al., 1995; Ihle, 1996) . JAK binding to cytokine receptors results in the cross-phosphorylation of both the receptors and JAK proteins. STATs then recognize and bind phosphorylated tyrosine residues on cytokine receptors by virtue of their src homology 2 (SH2) domains, undergoing tyrosine phosphorylation themselves by bound JAK proteins (Yeh and Pellegrini, 1999) . STAT molecules that have been tyrosine phosphorylated by JAKs subsequently dimerize in hetero-or homodimers and are translocated to the nucleus where they promote the transcription of a number of genes by direct DNA binding (Seidel et al., 1995) .
STATs have also been shown to undergo activation in response to a host of noncytokine growth factors including TGFa (Grandis et al., 1998; Fernandes et al., 1999) , EGF (Leaman et al., 1996a) and neu differentiation factor (Olayioyee et al., 1999) . However, under these conditions, the mechanism of STAT tyrosine phosphorylation is less well defined. A variety of receptor and nonreceptor tyrosine kinases, including EGFR, ErbB2, and src, have been shown to bind and activate STATs, in some cases directly and in others indirectly through intermediaries such as JAKs (reviewed in (Bowman et al., 2000a) ). Activation of STATs, by EGFR, for example, may occur through JAK-dependent (Garcia et al., 2001) or-independent mechanisms (Leaman et al., 1996b) , or EGFR may act in conjunction with src (Olayioyee et al., 1999; Garcia et al., 2001) . ErbB2 kinase inhibition alone has been shown to block the nuclear translocation of STAT3 (Fernandes et al., 1999) , however, elsewhere it has been suggested that ErbB2-associated STAT activation requires the participation of src (Olayioyee et al., 1999) .
Outside of normal cell signaling, STATs, particularly STAT3 and to a lesser extent STAT5, have been implicated in oncogenesis and constitutive STAT activation has been observed in a wide variety of human cancers (Bowman et al., 2000a) . STAT signaling contributes to malignant progression both through antiapoptotic effects and through the promotion of aberrant cell-cycle regulation. Cyclin D1 expression is elevated in cells transfected with a constitutively active form of STAT3 (Bowman et al., 2000b) , and v-srcinduced STAT3 activation has been shown to activate the expression of a cyclin D1 promoter-based reporter (Sinibaldi et al., 2000) . Alterations in p21
Cip1 levels associated with STAT1 and STAT3 signaling have been reported (Sinibaldi et al., 2000) , and the p21 Cip1 promoter is known to harbor three STAT-binding sites (Chin et al., 1996) . Additionally, c-myc, another transcription factor important in cell-cycle progression, contains a consensus STAT3-binding site within its promoter region (Kiuchi et al., 1999) . Fibroblast cell lines transfected with constitutively active STAT3 demonstrated increased levels of c-myc (Bowman et al., 2000b) as did NIH3T3 cells expressing v-src .
In this study, we used human PDAC cell lines MIA PaCa-2 and UK Pan-1 to investigate the role of ErbB2 in PDAC oncogenesis. Both these cell lines exhibit exogenous growth factor-independent proliferation that has been attributed to the production of autocrine growth factors and/or overexpression of growth factor receptors (Fralix et al., 2000) . Using a highly efficient pharmacologic inhibitor of ErbB2 kinase, tyrphostin AG879 (Osherov et al., 1993; Levitzki and Gazit, 1995) , we observed that ErbB2 kinase activity was required to maintain the exogenous growth factor-independent phenotype displayed by the PDAC cell lines. We investigated which downstream targets might mediate growth factor independence and established a causal link between STAT3 activation and ErbB2 kinase. Furthermore, STAT3 activation was required for ErbB2-induced proliferation. We believe that these findings indicate a novel mechanism of oncogenesis in PDAC and may suggest future therapeutic strategies in the treatment of PDAC.
Materials and methods

Reagents
All chemicals and reagents were purchased from Sigma (St Louis, MO, USA) unless otherwise noted. Antibody to phErbB2-Y1248 (cat#06-229) was obtained from Upstate Biotech (Lake Placid, NY, USA). Antibodies to cyclins A (sc-751), D1 (sc-717), D2 (sc-181), D3 (sc-182) , and E (sc-198), cdk 2 (sc-163), 4 (sc-260), and 6 (sc-177), p21 (sc-817), p27 (sc-1641), c-myc (sc-42), pRb (sc-50), STAT3 (sc-8019), phSTAT3 (sc-8059), and ErbB2 (sc-284) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Actin antibody (A-2066) was obtained from Sigma. Horseradish peroxidase-conjugated anti-mouse and anti-rabbit secondary antibodies were purchased from Pharmacia Biotechtechnology (Buckinghamshire, England, UK). AG879 (cat#658460), AG1478 (cat#658552), AG490 (cat#658401), and PP2 (cat#529573) inhibitors were purchased from Calbiochem (La Jolla, CA, USA). UK Pan-1 cells were originally established from a human pancreatic ductal adenocarcinoma and have been characterized previously (Fralix et al., 2000) .
Cell culture and stimulation
Cells were grown to 80% confluence in SDMEM (DMEM supplemented with 10% fetal bovine serum, amino acids, pyruvate, l-glutamine, and penicillin/streptomycin). Cells were then serum-starved in serum-free medium (SFM, DMEM with penicillin/streptomycin and l-glutamine only) for 5 days. For treatment with AG879, AG1478, AG490, or PP2, all compounds were dissolved in DMSO at a concentration of 1000 Â of the final indicated concentration. Drugs or DMSO alone as a vehicle control were added directly to the conditioned media and allowed to preincubate for 3 h. The final concentration of DMSO in the media of all cells during treatments was 0.1%. Fresh SFM was then added to stimulate the cells and contained the same dose of drug/DMSO as the preincubation dose.
Cell lysis
To obtain total cellular protein lysates, cells were washed twice with ice-cold PBS and lysed with 500 ml per 10 cm plate of TNESVS lysis buffer (Tris 50 mm pH 7.2-7.8, NP-40 1%, EDTA 2 mm, NaCl 100 mm, Na orthovanadate 10 mm, 0.1% sodium dodecyl sulfate (SDS), leupeptin (10 mg/ml), aprotinin (2 mg/ml), and phenylmethylsulfonyl fluoride 100 mm (protease inhibitors from Roche, Indianapolis, IN, USA)). Lysates were cleared by centrifugation at 15 000 r.p.m. for 10 min and protein concentrations were determined by the Pierce (Rockford, IL, USA) protein assay reagent.
Mitogenesis assays and cell cycle analysis
Cells were plated in a 96-well dish at a concentration of 5 Â 10 4 cells per well (200 ml/well) in SDMEM and grown to 80% confluence. After being serum-starved for 5 days, they underwent stimulation with SFM in the presence or absence of an inhibitor as described above. For [ 3 H]thymidine uptake assays, all treatment groups included six similarly treated wells. At 22 h after the introduction of fresh SFM, [ 3 H]thymidine at a concentration of 5 mCi/ml in SFM (1 mCi per well) was introduced into all wells and allowed to incubate for 2 h. The cells were then frozen at À801C for 24 h to halt cellular activity. After thawing at room temperature, cellular material was harvested on a Skatron cell harvester (Skatron Instruments, Sterling, VA, USA) as per the manufacturer's protocol. Total cellular and fluid contents of wells were aspirated and filtered onto borosilicate glass microfiber filter disks, which were then dried for 30 min at 601C. Cells were fixed in 70% ethanol and stained with propidium iodide. Flow cytometry was performed using a FACSCalibur (Becton-Dickinson, Immunocytomtery Systems, Inc., San Jose, CA, USA). Cells were illuminated with 15 mW of 488 nm laser light and PI fluorescence was read through a 670 nm long-pass filter. Data were collectecd on a Macintosh computer using Cell Quest software (BDIS). Cell-cycle analysis was performed with ModFit V3 software (Verity Software House, Topsham, ME, USA). Typically, 20 000 cells were analysed per sample.
Immunoblotting and immunoprecipitation
For immunoblotting, equal amounts of protein (25-50mg) were mixed 1 : 1 with 2 Â loading buffer (50 nm Tris HCl, 5% bmercaptoethanol, 2% SDS, 10% glycerol, 0.1%. bromophenol blue), boiled for 5 min, and then separated by SDS-PAGE. For analysis of phospho-pRb levels, a low crosslinker ratio gel of 30 : 0.4 acrylamide to bisacrylamide was used. All other gels employed a standard 29 : 1 acrylamide to bisacrylamide ratio. After SDS-PAGE, proteins were transferred to polyvinylidene difluoride membranes (Pharmacia Biotechtechnology, Buckinghamshire, England, UK). All blotting steps were carried out at room temperature with gentle rocking except as noted below. The membranes were blocked in blocking buffer consisting of 5% nonfat dry milk in Tris-buffered salineTween 20 (TBST-0.15 m NaCl, 0.01 m Tris HCl pH 7.4, 0.05% Tween 20). All antibodies were employed at a concentration of 1 mg/ml. Phospho-ErbB2 and phospho-STAT3 antibody incubation was performed for 2 h in TBST alone. All other blots were incubated with the indicated antibody in blocking buffer for 2 h at RT except for c-myc, p21, and p27 blots, which were incubated overnight at 41C. After washing, blots were incubated with a 1 : 2000 dilution of horseradish peroxidaseconjugated secondary antibody in blocking buffer for 2 h, followed by further washing. Enhanced chemiluminescence was performed according to the manufacturer's instructions (NEN, Boston, MA, USA). Immunoblotting for phosphoErbB2 and phospho-STAT3 was followed by membrane stripping at 601 for 25 min in stripping buffer (0.5 m Tris, pH 6.8, 2% SDS, 0.7% b-mercaptoethanol) and then reprobing with antibody to ErbB2 and STAT3, respectively. Western blots for cell cycle regulator levels underwent reprobing with actin antibody without stripping to confirm equal protein loading.
All immunoprecipitation steps were carried out at 41C. Cleared, quantitated protein lysates (300 mg) were transferred into new Eppendorf tubes and their volume made up to 400 ml in TNESVS buffer. The lysates (300 mg) were precleared by incubation with protein A agarose (20 ml/tube) for 30 min with gentle rocking. They were then centrifuged at 15 000 r.p.m. for 10 min, the supernatant transferred into a new-tube, and their total volume adjusted to 400 ml with TNESVS buffer. Next, 1.5 mg/tube of the indicated immunoprecipitation antibody was introduced and allowed to incubate for 4 h with gentle rotation, followed by the addition of 20 ml/tube protein A agarose and further incubation for 4 h. Tubes were then centrifuged for 2 min at 15 000 rpm, the supernatant was discarded, and the pellet was washed three times in fresh, icecold TNESVS buffer. The pellet was resuspended in 25 ml TNESVS þ 25 ml of 2 Â loading buffer, boiled for 10 min, and resolved by SDS-PAGE as described above. For the cdk2 immunoprecipitation, after immunoblotting for p27, the blot was reprobed for cdk2 without stripping the membrane. To assess receptor activation, lysates were immunoprecipitated with antibody to EGFR or ErbB2. Immunoprecipitates were then loaded on an 8% SDS-PAGE gel and immunoblotted with an antibody to phosphotyrosine, followed by stripping and reprobing with an antibody to the immunoprecipitated protein.
RT-PCR analysis of STAT3 isoforms
MIA PaCa-2 cells were stably transfected with pIRES/STAT3b or pIRES vector. Total RNA was extracted from cultured cells using TRIZOL reagent (Gibco-BRL, Gaithersburg, MD, USA) according to the manufacturer's protocol. RT-PCR was performed using a commercially available kit (Perkin Elmer Corp., Foster City, CA, USA) following the protocol given by the manufacturer. Amplification of the b-actin gene using specific primers was used as an internal control and to normalize expression levels. The PCR products were run on 2% agarose gels in TBE and stained with ethidium bromide. The primers were designed according to Caldenhoven et al. (1996) to amplify both STAT3a and STAT3b isoforms.
Immunohistochemistry
Immunohistochemistry was performed on formalinfixed paraffin-embedded tissue. Sections were heated to 601C, rehydrated in xylene and graded alcohols. Antigen retrieval was performed with 10 mm citrate buffer at pH 6.0 for 20 min in a 95% water bath. Slides were then allowed to cool for another 20 min, followed by sequential rinsing in PBS and TBS-T (Tris-HCl 0.05 m pH 7.6, NaCl 0.15 m, Tween 20 0.1%). Endogenous peroxidase activity was quenched by incubation in TBS-T containing 0.1% sodium azide and 3% hydrogen peroxide. Each incubation step was carried out at RT and was followed by three sequential washes (5 min each) in TBS-T. Sections were incubated in primary antibody diluted in TBS-T containing 1% ovalbumin and 1 mg/ml sodium azide (1 h), in biotinylated as secondary antibody for 15 min, followed by peroxidase-labeled streptavidin for 15 min (LSAB-2 Dako Corp., Carpenteria, CA, USA) then diaminobenzidine chromogen substrate (Dako Corp., Carpenteria, CA, USA) along with DAB enhancer (Signet) for 10 min. Slides were counterstained with hematoxylin and mounted.
Results
Effect of ErbB2 and EGFR kinase inhibition on pancreatic cancer cell proliferation
The production of autocrine growth factors was originally postulated as a means by which cancer cells may acquire a selective growth advantage over normal cells in vivo (Sporn and Todaro, 1980; Sporn and Roberts, 1985) . The overexpression of autocrine growth factors and/or their receptors has been repeatedly shown to allow cancer cells to undergo proliferation in the absence of serum or exogenous growth factors in the culture medium (Ziober et al., 1993; Howell et al., 1998a, b; Jiang et al., 1998a, b) . This continued growth in the absence of exogenous growth factors is referred to as growth factor Autocrine-mediated ErbB-2 kinase D DeArmond et al independence. MIA PaCa-2 and UK Pan-1, cell lines derived from PDAC, exhibit a growth factor-independent phenotype (Freeman et al., 1995; Fralix et al., 2000) . To assess whether EGFR and/or ErbB2 was contributing to this growth factor-independent phenotype, a highly selective inhibitor of EGFR kinase, tyrphostin AG1478, and of ErbB2 kinase, tyrphostin AG879, were used in [ 3 H]thymidine uptake assays. MIA PaCa-2 cells were made quiescent by serum deprivation and then stimulated with SFM to evaluate autocrine-induced proliferation by EGFR and ErbB2 signaling. The dose initially chosen for AG879 was its reported IC 50 (1 mm) for ErbB2 kinase (Ohmichi et al., 1993) . This dose completely inhibited SFM-induced mitogenesis in MIA PaCa-2 ( Figure 1a) . As a result of the extent of inhibition displayed by AG879, a dose-response curve was constructed to rule out a toxic effect (Figure 1b) . Doses of AG879 as low as 0.5 mm were inhibitory while a dose of 0.1 mm had no effect, establishing a pattern of highly specific pharmacodynamics. Inhibition of EGFR kinase activity by AG1478, in contrast, produced only a partial inhibition of mitogenesis in MIA PaCa-2 ( Figure 1a) . The reported IC 50 of AG1478 for EGFR kinase is 0.003 mm (Levitzki and Gazit, 1995) . We found that a dose of 5 mm AG1478 was needed to inhibit completely the tyrosine phosphorylation of EGFR induced by EGF in MIA PaCa-2 (not shown). Furthermore, this dose of the EGFR inhibitor only partially blocked SFM-induced proliferation, suggesting that the lesser inhibition by AG1478 treatment was not due to incomplete inhibition of EGFR kinase activity. UK Pan-1 cells assayed in the same manner showed a similar sensitivity to treatment with tyrphostins ( Figure 1c) , indicating that the role of ErbB2 in growth factor independence is not restricted to a single PDAC cell line.
The growth-inhibitory effects observed by [ 3 H]thymidine uptake after treatment of cells with tyrphostins were collaborated by experiments using flow cytometry. These experiments show that 71% of the cells were in G1 after 5 days of serum deprivation, and 19% remained in the S phase suggesting that the cells were partially quiescent (Figure 1d ). However, stimulation of these cells with SFM led to a greater than two fold increase in the S phase fraction (43% compared to 19%) and decreased the G1 phase fraction from 71 to 38% indicating that arrested cells were able to re-enter the cell cycle (Figure 1d ). In agreement with the results of tritiated-thymidine incorporation, flow cytometry analysis showed that treatment of cells with AG1478 or AG879 partially blocked cell-cycle progression. Also in agreement with the thymidine uptake studies, the ErbB2 kinase inhibitor AG879 was a more effective growth inhibitor than the EGFR kinase inhibitor AG1478 (Figure 1d ). We concluded that ErbB2 kinase activity is required for the exogenous growth factor-independent mitogenesis of MIA PaCa-2, while EGFR contributes to this mitogenesis only in part.
Inhibition of ErbB2 by AG879 leads to diminished tyrosine phosphorylation of ErbB2 at Y1248
On the ErbB2 molecule, Y1248 has been identified as a site of tyrosine phosphorylation important for the activation of intracellular mitogenic signaling pathways. Several commercially available anti-ErbB2 antibodies targeted to phosphotyrosine at this site have been developed. Both MIA PaCa-2 and UK Pan-1 cells displayed readily detectable levels of constitutively activated ErbB2 as measured by phosphorylation at Y1248 (Figure 2a, b) . SFM stimulation produced an increase in ErbB2 phosphorylation at this site ( Figure  2a, b) . Treatment of MIA PaCa-2 and UK Pan-1 cells with AG879 inhibited SFM-induced phosphorylation of ErbB2 (Figure 2a, b) , while in MIA PaCa-2 treatment with AG1478 appeared to exert a slightly lesser effect (Figure 2a) .
Similarly, stimulation with EGF caused an increase in phosphorylation of ErbB2 as measured by either Western blotting using the antibody that recognizes the Y1248 site (not shown) or by immunoprecipitating ErbB2 followed by Western blotting using the antibody to phosphotyrosine (Figure 2c ). In the presence of exogenous EGF, it appears that both the level of ErbB2 and phosphorylation of ErbB2 were decreased, whether measured by immunoprecipitation of ErbB2 (Figure 2c) or by Western blot analysis (Figure 2d ). It is unclear as to why the level of ErbB2 would be downregulated, although this might represent an increase in receptor internalization. It is reasonable to assume that although AG879 may block autophosphorylation by ErbB2 kinase, trans-phosphorylation by EGFR kinase of ErbB2 may still occur in the presence of high levels of exogenous EGF. The specificity of the AG879 was further determined by showing that AG879 did not inhibit the phosphorylation of EGFR by EGF, whereas, AG1478 almost completely blocked EGF-mediated phosphorylation of EGFR (Figure 2d ).
Inhibition of ErbB2 by AG879 diminishes the level of tyrosine phosphorylation of STAT3
We next examined the downstream effector molecules that might mediate ErbB2 kinase-induced cell proliferation. Interestingly, stimulation of cells with SFM did not cause an increase in the phosphorylation of either ERKs or Akt above the low level of constitutive activation seen in quiescent cells (not shown). This finding suggests that other target molecules may be required for autocrinemediated growth. One potential family of molecules involved in cell proliferation are the STATs (Ihle, 1996) . Of the various STAT family members, STAT3 is most frequently identified with proliferative signaling in human cancer (Bowman et al., 2000a) . Activation of STAT3 has been linked to the induction of cyclin D1 (Bowman et al., 2000b; Sinibaldi et al., 2000) and the inhibition of cdki expression (Chin et al., 1996; Sinibaldi et al., 2000) . Cytokine activation of STAT3 is known to occur through interleukin receptors. Interleukin receptors lacking intrinsic tyrosine kinase domains require the recruitment of Janus kinases (JAKs) to activate STAT pathways. However, JAKindependent STAT activation by receptor tyrosine kinases of the ErbB family has been reported (Leaman et al., 1996a; Fernandes et al., 1999) .
Autocrine-mediated
To examine the role of STAT3 in pancreatic cancer cells, a time course for STAT3 activation after SFM stimulation was established in MIA PaCa-2 (Figure 3a) . STAT3 activation in quiescent MIA PaCa-2 cells was readily detectable and was increased at 5 h after the introduction of fresh SFM, although an initial decrease in activation levels was observed (Figure 3a) . These findings suggested that the replacement of conditioned media with fresh SFM initially led to a decrease in the concentration of some autocrine factor produced by MIA PaCa-2 that was responsible for STAT3 activation, and that an interval similar to that associated with de novo protein synthesis was required to replenish the levels of this factor in the medium. When MIA PaCa-2 cells were treated with AG879, the SFM-associated increase in STAT3 activation was completely inhibited both in MIA PaCa-2 ( Figure 3b ) and in UK Pan-1 (Figure 3c ). Treatment with AG1478 showed a partial inhibition of STAT3 activation ( Figure 3b) ; however, treatment with AG490, a tyrphostin inhibitor of JAK2, had no effect (Figure 3b) , suggesting that the SFM-associated activation of STAT3 was primarily dependent on ErbB2, partially dependent on EGFR, and independent of JAK kinase activity. Furthermore, treatment of PDAC cells with PP2, an inhibitor of src kinase activity, failed to inhibit SFM-induced STAT3 phosphorylation at the 5 h time point as shown for UK Pan-1 cells (Figure 3c ). Cells were serum-starved and then stimulated for 15 min with EGF and vehicle alone (DMSO) or with AG879. Cell lysates were immunoprecipitated with an antibody for erbB2; immunoprecipitated proteins were separated by SDS-PAGE and subjected to Western blot analysis using an antibody specific for phosphorylated tyrosine or total erbB2. (d) Western blot analysis used to corroborate the results of immunoprecipitation, which indicate that treatment of cells with AG879 downregulates phosphorylation of erbB2 after stimulation by EGF. Phosphorylated erbB2 was detected using an antibody specific for erbB2 phosphorylated at tyrosine residue at amino-acid position 1248 (P-ErbB2) or to total erbB2 (T-ErbB2). (e) Control showing the specificity of AG879. Treatment of cells with AG879 did not prevent EGF-mediated phosphorylation of EGFR. ErbB2 or EGFR was immunoprecipitated as described in the Materials and methods, and total tyrosine phosphorylation was detected. Immunopreciptiates were then loaded on an 8% SDS-PAGE gel and immunoblotted with RC20 to determine the level of tyrosine phosphorylation, followed by stripping and reprobing with the antibodies to the immunoprecipitated proteins Autocrine-mediated ErbB-2 kinase D DeArmond et al
Inhibition of ErbB2 by AG879 decreases the association of ErbB2 with STAT3
In MIA PaCa-2 cells, STAT3 was readily detectable in ErbB2 immunoprecipitates (Figure 4) . SFM stimulation of MIA PaCa-2 resulted in an increased association of STAT3 with ErbB2 (Figure 4) , mirroring the pattern of STAT3 activation previously observed under the same conditions (Figure 2b ). This SFM-induced association was inhibited by treatment with AG879 ( Figure 4 ). AG1478 treatment only partially inhibited STAT3-ErbB2 coimmunoprecipitation (Figure 4) , consistent with its lesser inhibition of ErbB2 phosphorylation at Y1248 in MIA PaCa-2 (Figure 2a ) and suggesting that STAT3 requires a phosphorylated Y1248 site for binding to ErbB2.
Modulation of G1 cell-cycle regulator levels by inhibition of ErbB2 kinase
The results of the [ 3 H]thymidine assays and analysis of flow cytometry experiments (Figure 1 ) indicated that the transition from the G0/G1 to the S phase induced by SFM in pancreatic cancer cell lines was being blocked by the inhibition of ErbB2 kinase activity. We therefore examined the levels of G1 cell-cycle regulators by Western blotting after stimulation with SFM in the presence or absence of AG879 or AG1478. This analysis involved MIA PaCa-2 cells that had been stimulated for 24 h with SFM to coincide with the time course of the mitogenesis assays.
The transition from the G0/G1 to the S phase is marked by a complex interplay of cyclins, cdks, and cdk inhibitors that results in enhanced cyclin/cdk association and kinase activity. This may occur through numerous mechanisms including increased expression of cyclins and diminished expression of ckis. Stimulation of quiescent MIA PaCa-2 cells with SFM resulted in only subtle changes in cell-cycle regulators that included a slight decrease in the level of the cdk inhibitor p21 Cip1 and an increase in cyclin A and c-Myc ( Figure 5 ). However, when MIA PaCa-2 cells were pretreated with AG879 prior to SFM stimulation, the levels of cyclins D1-3 and E were diminished and an increase in the levels of p21
Cip1 and p27 Kip1 was detected ( Figure 5 ). AG1478 treatment resulted in a reduction in cyclin D3 and cyclin E levels; however, no alteration of p21 Cip1 or p27
Kip1 levels was detected ( Figure 5 ). The role of c-myc in promoting cell-cycle progression has been studied and involves, at least in part, the modulation of cellcycle regulators at the transcriptional level. Additionally, crosstalk between c-myc and ErbB signaling has been reported in several studies (Bartkova et al., 1997; Cheng et al., 1999) . In MIA PaCa-2 cells, re-entry into G1 by the addition of fresh SFM to quiescent cells led to an induction of c-myc at 24 h ( Figure 5 ). Inhibition of ErbB2 kinase blocked SFM induction of c-myc; however, inhibition of EGFR activation had no effect on c-myc levels ( Figure 5 ).
Inhibition of ErbB2 kinase promotes Cdk2-p27
Kip1 association and blocks pRb phosphorylation Early in G1, the presence of high levels of D cyclins serves a dual function in the transition to the S phase. D cyclins associate with cdk4 and -6 to form a complex that is kinase-active for the phosphorylation of pRb. Additionally, D cyclins complexed to cdk4 and cdk6 bind p21 Cip1 and p27
Kip1
, preventing the latter from forming an inhibitory association with cyclin E/cdk2 complexes. In MIA PaCa-2, quiescent cells showed a readily detectable association of p27
Kip1 with cdk2 that was diminished upon stimulation with fresh SFM (Figure 6a) . Inhibition of ErbB2 kinase activity with AG879 resulted in a significant increase in association with p27
Kip1 with cdk2; however, no such effect was seen with AG1478 ( Figure 6a ). When cyclin E/cdk2 complexes are inhibited by association with p27 Kip1 , their ability to phosphorylate pRb causing a release of E2F transcription factors is impaired. In MIA PaCa-2, the introduction of fresh SFM resulted in pRb phosphorylation that was inhibited by treatment with AG879, but not AG1478 (Figure 6b ).
Inhibition of ErbB2 by AG879 treatment blocks early cyclin D1 induction
Cyclin D1 induction occurs early in the complex sequence of events underlying the G0/G1 to the S phase progression. As a result of the possibility that an ErbB2-dependent induction of cyclin D1 occurring prior to the 24 h time point could have accounted for the cell-cycle arrest induced by inhibition of ErbB2 kinase, a time course for cyclin D1 levels was conducted (data not shown). It was determined that at 5 h after SFM stimulation of quiescent MIA PaCa-2 cells, cyclin D1 levels reached a peak that was measurably higher than quiescent levels (Figure 7a ). In MIA PaCa-2 cells that were treated with AG879, this early induction of cyclin D1 was completely inhibited, while AG1478 showed only minimal effects (Figure 7a) . Similar results were obtained in UK Pan-1 cells (Figure 7b) . Notably, the levels of cyclin D1 expression were closely correlated with the pattern of STAT3 activation observed in both cell lines (Figure 2a-c) , implying that STAT3 signaling could play a role in the induction of cyclin D1. Kipl and decreases the association of cyclin E and cdk2 and subsequent phosphorylation of pRb. Quiescent MIA PaCa-2 cells (Q) and quiescent MIA PaCa-2 cells stimulated with fresh SFM in the presence or absence of AG879 and AG1478 at indicated concentrations or DMSO alone as a vehicle control (C) for 24 h were harvested for total cellular protein lysates in TNESVS buffer. (a) Cleared protein lysates were immunoprecipitated using anti-cdk2 antibody, then immunoblotted for either cdk2 or p27
Kip1 . (b) Protein lysates were separated on an 8% polyacrylamide gel containing a 30 : 0.4 ratio of acrylamide to bisacrylamide and immunoblotted with antibody to pRb. More phosphorylated forms of pRb migrate more slowly (upper arrow at right) than dephosphorylated forms (lower arrow at right) allowing for a determination of pRb phosphorylation levels by the migration pattern of pRb Autocrine-mediated ErbB-2 kinase D DeArmond et al STAT3 is required for growth factor independence in MIA PaCa-2 cells
The data presented here indicate that ErbB2 kinase activity is required for autocrine-mediated activation of STAT3 and that phosphorylation of ErbB2 is necessary for the coassociation of ErbB2 and STAT3. Furthermore, autocrine stimulation of cell proliferation and activation of G1 cyclins required ErbB2 kinase. However, it is not clear from these data whether STAT3 acting downstream of ErbB2 mediates any of these ErbB2 effects on cell proliferation. To address this possibility, we examined the effects of expressing a dominant-negative STAT3 protein, STAT3b, on cell proliferation. STAT3b lacks a transactivation domain that is known to block STAT3 function when expressed in different cell types (Catlett-Falcone et al., 1999) . MIA PaCa-2 cells were stably transfected with a STAT3b expression construct (pIRES-STAT3 b) or with the empty vector (pIRESvector). Stable transfectants were selected that expressed a PCR product of appropriate size for STAT3b (Figure 8a ). These transfectants were compared with vector-transfected controls and with the parental MIA PaCa-2 cell line for autocrine-mediated cell proliferation. Serum-starved, quiescent cells were stimulated with serum-free or EGF-containing media and cell proliferation was measured by [ 3 H]thymidine incorporation.
STAT3b transfectants were not stimulated to proliferate by fresh SFM or media containing EGF (Figure 8b ), whereas, a vector control transfectant or the parental cell A measure of 2 mg of total RNA was reverse transcribed into cDNA and 1/4 of the cDNA was amplified by PCR. The primers were designed according to Caldenhoven et al. (1996) to amplify both STAT3a and STAT3b isoforms. Clones 22 and 49 express the correct molecular size band for the STATb isoform. MW, molecular weight markers; P, parental; V, vector pool, 22 and 49 represent two STATb clones. (b) STAT3b blocked the growth factor-independent growth of MIA PaCa-2 cells. MIA PaCa-2 parental cells and MIA PaCa-2/STAT3b clones were plated at 2 Â 10 4 cells/well in a 96-well plate. At 24 h after plating, the cells were made quiescent by depletion of serum for 4 days, then released from quiescent by stimulating the cells with fresh SFM or SFM plus 50 ng/ml of EGF for 24 h. Kip1 expression levels increased dramatically and that cyclin D1 expression was decreased in serumstarved MIA PaCa-2 cells that were transfected with STAT3b compared to vector-transfected control cells Autocrine-mediated ErbB-2 kinase D DeArmond et al line was stimulated to proliferate with SFM, and the level of proliferation was even greater when cells were stimulated with addition of EGF to the media (Figure 8b ). These data are consistent with the hypothesis that STAT3 function was required for ErbB2 kinasemediated cell proliferation. MIA PaCa2 cells are somewhat resistant to becoming quiescent when exogenous growth factors are removed and these cells show constitutive activation of STAT3 that is mediated by ErbB2 kinase. We speculated that STAT3 also played a role in rapid release from G1 and also in resistance of these cells to becoming quiescent. To begin to explore this latter possibility, we compared levels of the cdki, p27 Kip1 , and cyclin D1 in MIA PaCa-2 vector control cells and in MIA PaCa-2 STAT3b transfectants. This experiment shows that inhibiting the function of STAT3 caused an increase in the level of induction of p27
Kip1 and an overall decrease in the level of cyclin D1 (Figure 8c ). These data are consistent with a role for STAT3 in cell-cycle progression.
Coexpression of ErbB2 and activated STAT3 in human PDAC specimens
We used immunohistochemistry as a first step in assessing the relevance of an ErbB2/STAT3 pathway in human PDAC (Figure 9 ). Strong STAT3 staining was detected in 10 of 11 specimens. Similary, ErbB2 staining was detected in tumor areas of nine of 11 pancreatic cancer specimens, with eight of these nine specimens showing a strong level of staining. Phosphorylated STAT3 was detected in all nine specimens that were strongly positive for ErbB2. One of the 11 pancreatic cancer specimens lacked staining for either ErbB2 or STAT3 (Table 1) . Nontumor tissue was found in seven of the 11 specimens. ErbB2 and STAT3 were detected in the ductal epithelial compartment of only one of these seven nontumor tissue areas, which represented an area of pancreatitis. ErbB2 and STAT3 were detected in some tissue areas outside the ductal compartment. These included acini or islet cells. In addition, staining for STAT3, but not ErbB2, was detected in the nuclei of connective tissues with some focal staining of vessels (not shown in table). The costaining of STAT3 and ErbB2 in eight of 11 tumor specimens and the general absence of ErbB2 and STAT3 staining in nontumor ductal epithelial cells (only one of seven) was highly significant (P-value 0.0128 by Fisher's exact test). Moreover, the coexpression of ErbB2 and STAT3 in most tumor tissue is consistent with the ErbB2/STAT3 pathway identified in pancreatic cancer cell lines. The occurrence of STAT3, but not ErbB2, in lymphocytes and vessels suggests that signaling other than by erbB2 activates STAT3 in these cell types. 
Discussion
ErbB2 overexpression in PDAC has been reported in several studies (Hall et al., 1990; Yamanaka et al., 1993; Jaskiewicz et al., 1994; Dugan et al., 1997) . However, none of these has addressed the role that ErbB2 plays in promoting tumorigenesis at the cellular level in PDAC or the extent to which ErbB2 function in PDAC differs from or resembles its function in other cancer types. In the present study, we explored these issues through the use of PDAC cell lines, which display exogenous growth factor-independent phenotypes. Growth factor independence is a hallmark of cancer cells that betokens a profound departure from normal cellular physiology (Sporn and Todaro, 1980; Sporn and Roberts, 1985; Ziober et al., 1993; Howell et al., 1998a, b) . Growth factor-independent cells are associated with more malignant tumor types and exhibit faster tumor growth in nude mice as compared to growth factor-dependent cancer cells (Ziober et al., 1993; Jiang et al., 1998a) . In the PDAC cell lines considered here, growth factor independence was demonstrated by the ability of quiescent cells to undergo S-phase entry as measured by [
3 H]thymidine uptake in the presence of serum and exogenous growth factor-free medium (SFM). By using a highly selective tyrphostin inhibitor of ErbB2 tyrosine kinase, AG879, we show that ErbB2 kinase activity was required for SFM-induced mitogenesis in both the PDAC cell lines studied (Figure 1a, c) . In contrast, treatment with AG1478, an inhibitor of EGFR kinase, only partially reduced SFM-induced mitogenesis in MIA PaCa-2 (Figure 1a) . AG879 has been employed in several studies as a highly specific inhibitor of ErbB2, with a reported IC 50 for ErbB2 kinase of 1 mm; however, pharmacologic inhibitors have the potential for toxicity and/or nonspecificity of action (Osherov et al., 1993) . Owing to these concerns, a dose-response curve for the effect of AG879 on mitogenesis was established (Figure 1b ). Doses as low as 0.5 mm AG879 inhibited mitogenesis completely while 0.1 mm showed no effect (Figure 1b ). This pattern of inhibition indicates a very specific mechanism of action for AG879 and argues against toxic effects. Furthermore, 0.5 and 1 mm AG879 effectively inhibited heregulin-induced ErbB2 and ErbB3 activation in MIA PaCa-2, but did not affect EGF-associated phosphorylation of EGFR (not shown). These findings indicated that doses of AG879 that were inhibitory for ErbB2 did not inhibit EGFR and were consistent with the action of AG879 as previously described (Osherov et al., 1993) .
ErbB2 overexpression has been associated with aberrant cell-cycle regulation, which is thought to provide cancer cells with a selective growth advantage. The fact that ErbB2 kinase inhibition produced such a profound blockade of SFM-induced mitogenesis led us to hypothesize that ErbB2 was contributing to aberrant cell-cycle regulation in the PDAC cell lines. To test this hypothesis, we examined the protein levels of cell-cycle regulators in MIA PaCa-2 after treatment with the inhibitors. In cells treated with AG879, we found significantly diminished levels of cyclins A, D1, D2, and E and increased levels of p21
Kip1
( Figure 5 ). Treatment with AG1478 resulted in diminished levels of cyclins D3 and E, slightly diminished levels of cyclins A and D2 but, most notably, no increase in either p21 Cip1 or p27 Kip1 ( Figure 5 ). Additionally, (Figure 5 ), suggesting that c-myc, a transcription factor important in cell-cycle progression, is induced by ErbB2 signaling in the PDAC cell lines. Significantly, ErbB2 inhibition led to a blockade of SFM-associated early cyclin D1 induction in both PDAC cell lines (Figure 4a, b) . EGFR inhibition partially blocked cyclin D1 induction in MIA PaCa-2 (Figure 4a ). These findings support a close link between ErbB2 signaling and aberrant cyclin D1 expression in PDAC that has previously been reported for other tumor types Busse et al., 2000; Harari and Yarden, 2000) . Inhibition of ErbB2 led to an increased association of cdk2 with p27
, an inhibitory association that results in decreased kinase activity of cyclin E/cdk complexes (Figure 6a ). This increase in p27 Kip1 /cdk2 association is most likely explained by the synergistic effects of increased p27
Kip1 and decreased cyclin D1 protein levels observed after AG879 treatment (Figures 4a, 5 ), leading to an inability of cyclin D1 to shunt p27
Kip1 away from cyclin E/cdk2 complexes. Finally, inhibition of ErbB2 and, to a lesser extent, of EGFR kinase led to a decrease in the phosphorylation of pRb (Figure 6b ). We conclude that the inhibition of SFM-induced mitogenesis observed after AG879 treatment in the PDAC cell lines was due to the inhibition of cell-cycle progression and that ErbB2, in part assisted by EGFR, promotes aberrant cell-cycle regulation in PDAC.
ErbB2 overexpression has previously been linked to aberrant cell-cycle regulation via activated mitogenic signaling pathways, classically the ras/MAPK and PI3 K pathways (Harari and Yarden, 2000; Busse et al., 2000) . MAPK signaling has been shown to upregulate cyclin D1 expression at the transcriptional level while the PI3 K pathway contributes to post-translational stabilization of cyclin D1 protein (Basso et al., 2002) . Both UK Pan-1 and MIA PaCa-2 have mutations in ras and exhibit high levels of constitutive Erk activation. However, activated levels of Erks, AKT, and PLCg did not change after SFM stimulation either in the presence or absence of inhibitors (data not shown). This suggests that sufficient levels of these activated molecules are present in quiescent cells and that only a replenishment of nutrients is needed for cells to re-enter the cell cycle. Alternatively, activation of other target molecules may be required to mediate autocrine growth. SFM stimulation did result in increased levels of phospho-STAT3 in both cell lines that displayed a reproducible pattern across multiple experiments (Figure 3a) . In the first few hours after SFM stimulation, activated STAT3 levels decreased in comparison to constitutive levels, then increased, peaking at 5 h and remaining elevated for as long as 24 h after SFM introduction (Figure 3a) . This pattern suggests that the autocrine expression by MIA PaCa-2 of a growth factor is responsible for maintaining STAT3 in an activated state. SFM-induced activation of STAT3 was blocked at the 5 h time point by inhibition of ErbB2 kinase, but not by JAK or src kinase inhibition (Figure 3b, c) . However, additional molecular approaches are needed in future studies to determine whether these nonreceptor tyrosine kinases that are known to interact with ErbB2 (Olayioyee et al., 1999) play a role in ErbB2-mediated activation of STAT3. EGFR inhibition partially blocked STAT3 activation at 5 h in MIA PaCa-2 (Figure 3b ). Of note, STAT3 activation was partially blocked by src kinase inhibition at 7 h after SFM stimulation (data not shown), indicating that src may participate in a multistep optimization of STAT3 activation in PDAC cell lines. STAT3 coimmunoprecipitated with ErbB2 showing an increased association at 5 h after SFM stimulation. The association of ErbB2 and STAT3 was prevented by inhibition of ErbB2 kinase and to a much lesser extent by inhibiting EGFR activation (Figure 4 ). This finding may be explained by the fact that phosphorylation of ErbB2 at Y1248 was inhibited more efficiently by ErbB2 than by EGFR kinase blockade in MIA PaCa-2 (Figure 2a ). This suggests that STAT3, through its known SH-2 domain, may employ phosphorylated Y1248 as a docking site for ErbB2-associated activation.
Noncytokine STAT signaling remains poorly defined, both in terms of the mechanism by which STAT activation occurs and the cellular physiological consequences of that activation. The data we present here suggest that, in the PDAC cell lines studied, mitogenic signals from ErbB receptors may be mediated at least in part by STAT3. As we have shown here that ErbB2 kinase activation of STAT3 is required for the maintenance of aberrant, growth factor-independent cell cycling in PDAC cell lines, the above data suggest that STAT3 may function through its recognized ability to modulate cell-cycle regulators (Catlett-Falcone et al., 1999) . Furthermore, the data suggest that ErbB2 may bind and phosphorylate STAT3 directly. Alternatively, ErbB2 may work in conjunction with an as yet unidentified partner other than JAK or src. ErbB2 has been shown to interact with the IL-6 receptor gp130 in the IL-6-associated activation of STATs. Clearly, EGFR contributed to STAT3 activation in our study since treatment with AG1478 partially inhibited STAT3 activation ( Figure 3b ) and slightly diminished the association of ErbB2 with STAT3 (Figure 4) . EGFR may act to phosphorylate ErbB2 on key tyrosine residues such as Y1248, creating docking sites for the binding of STAT3 via its SH2 domain. The small but measurable role of EGFR also suggests that the autocrine growth factor responsible for the activation of STAT3 in PDAC cell lines belongs to the ErbB family of growth factors, although its exact identity remains to be elucidated.
In summary, this study indicates the presence of an ErbB2/STAT3 pathway that is required for maintenance of the growth factor-independent phenotype of PDAC cell lines MIA PaCa-2 and UK Pan-1. The existence of this pathway in pancreatic tumors is further supported by our finding of constitutively expressed phosphorylated STAT3 and coexpression of ErbB2 in these tumors. The finding of phosphorylated STAT3 has recently been reported to occur in several tumor types (Basso et al., 2002; Burke et al., 2002; Masuda et al., 2002; Schaefer et al., 2002) . It remains to be determined whether ErbB2 regulates STAT3 activation in these other tumor types. In this study, ErbB2 kinase activity was required for the induction of cyclin D1 and downregulating cdki during the G1 phase of the cell cycle. These studies further suggest that these ErbB2 effects on cell-cycle machinery are mediated in part through STAT3. However, further studies are needed to assess this possibility and to determine other potential downstream targets of the ErbB2/STAT3 pathway.
